Skip to main content
Top
Published in: Nuclear Medicine and Molecular Imaging 2/2016

Open Access 01-06-2016 | Interesting Image

Detection of Synchronous Parathyroid Adenoma and Breast Cancer with 18F-Fluorocholine PET-CT

Authors: Wessel MCM Vorselaars, Wouter P. Kluijfhout, Menno R. Vriens, Carmen C. van der Pol, Inne HM Borel Rinkes, Gerlof D. Valk, Bart de Keizer

Published in: Nuclear Medicine and Molecular Imaging | Issue 2/2016

Login to get access

Excerpt

A 71-year-old woman was referred to our tertiary care center for evaluation of asymptomatic recurrence of primary hyperparathyroidism. As per our protocol, the patient underwent neck/mediastinum 18F-fluorocholine (FCH) positron emission tomography-computed tomography (PET-CT) for localization. In our institution, FCH PET-CT is performed in patients with hyperparathyroidism and negative conventional imaging [1]. FCH PET-CT is a promising new imaging modality for detection of hyperfunctioning parathyroid glands [2, 3]. Thirty minutes after injection of 139 MBq (3.8 mCi), the PET-CT images showed a focal uptake (SUVmax = 1.8) at the lower anterior neck, level VI, anterior to the right common carotid artery (Fig. 1a-f), suspicious for parathyroid adenoma. Additionally, it showed a second focal uptake (SUVmax = 2.5) in a nodal structure measuring 1.2 cm, within the outer lower quadrant of the right breast (Fig. 2a-f). No other pathological uptake was seen. On the subsequent ultrasound (US) of the breast, there was an area of microcalcifications seen with no definite abnormal lesion. US of the axilla was negative for any suspicious lesions. Mammography showed a blurry 1.3-cm mass without clear boarders and microcalcifications within relatively dense fibro-glandular tissue (BI-RADS IV). US-guided core biopsy showed papillary carcinoma. Pathological examination after breast-conserving surgery revealed papillary breast cancer of 1.0 cm, staged pT1N0. The location of the cancer corresponded with that indicated by FCH PET-CT. Due to the finding of breast cancer, surgery for primary hyperparathyroidism was postponed.
Literature
1.
go back to reference Kluijfhout WP, Vorselaars WM, Vriens MR, et al. Enabling minimal invasive parathyroidectomy for patients with primary hyperparathyroidism using Tc-99m-sestamibi SPECT-CT, ultrasound and first results of (18)F-fluorocholine PET-CT. Eur J Radiol. 2015. doi:10.1016/j.ejrad.2015.05.024.PubMed Kluijfhout WP, Vorselaars WM, Vriens MR, et al. Enabling minimal invasive parathyroidectomy for patients with primary hyperparathyroidism using Tc-99m-sestamibi SPECT-CT, ultrasound and first results of (18)F-fluorocholine PET-CT. Eur J Radiol. 2015. doi:10.​1016/​j.​ejrad.​2015.​05.​024.PubMed
2.
go back to reference Michaud L, Burgess A, Huchet V, et al. Is 18F-fluorocholine-positron emission tomography/computerized tomography a new imaging tool for detecting hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism? J Clin Endocrinol Metab. 2014;99:4531–6.CrossRefPubMed Michaud L, Burgess A, Huchet V, et al. Is 18F-fluorocholine-positron emission tomography/computerized tomography a new imaging tool for detecting hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism? J Clin Endocrinol Metab. 2014;99:4531–6.CrossRefPubMed
3.
go back to reference Lezaic L, Rep S, Sever MJ, et al. 18F-fluorocholine PET/CT for localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism: a pilot study. Eur J Nucl Med Mol Imaging. 2014;41:2083–9.CrossRefPubMed Lezaic L, Rep S, Sever MJ, et al. 18F-fluorocholine PET/CT for localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism: a pilot study. Eur J Nucl Med Mol Imaging. 2014;41:2083–9.CrossRefPubMed
4.
go back to reference Senkus E, Kyriakides S, Penault-Llorca F, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi7–vi23.CrossRefPubMed Senkus E, Kyriakides S, Penault-Llorca F, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi7–vi23.CrossRefPubMed
5.
go back to reference Calderella C, Treglia G, Giordano A. Diagnostic performance of dedicated positron emission mammography using fluorine-18-fluorodeoxyglucose in women with suspicious breast lesions: a meta-analysis. Clin Breast Cancer. 2014;14:241–8.CrossRef Calderella C, Treglia G, Giordano A. Diagnostic performance of dedicated positron emission mammography using fluorine-18-fluorodeoxyglucose in women with suspicious breast lesions: a meta-analysis. Clin Breast Cancer. 2014;14:241–8.CrossRef
6.
go back to reference Berg WA, Zhang Z, Lehrer D, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA. 2012;307:1394–404.CrossRefPubMedPubMedCentral Berg WA, Zhang Z, Lehrer D, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA. 2012;307:1394–404.CrossRefPubMedPubMedCentral
7.
go back to reference Dorrius MD, de Vries EF, Slart RH, et al. Breast cancer: a new imaging approach as an addition to existing guidelines. Eur J Nucl Med Mol Imaging. 2015;42:813–7.CrossRefPubMed Dorrius MD, de Vries EF, Slart RH, et al. Breast cancer: a new imaging approach as an addition to existing guidelines. Eur J Nucl Med Mol Imaging. 2015;42:813–7.CrossRefPubMed
8.
go back to reference Glunde K, Jie C, Bhujwalla ZM. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res. 2004;64:4270–6.CrossRefPubMed Glunde K, Jie C, Bhujwalla ZM. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res. 2004;64:4270–6.CrossRefPubMed
9.
go back to reference Contractor KB, Kenny LM, Stebbing J, et al. [11C]choline positron emission tomography in estrogen receptor-positive breast cancer. Clin Cancer Res. 2009;15:5503–10.CrossRefPubMed Contractor KB, Kenny LM, Stebbing J, et al. [11C]choline positron emission tomography in estrogen receptor-positive breast cancer. Clin Cancer Res. 2009;15:5503–10.CrossRefPubMed
10.
go back to reference Kwee SA, DeGrado TR, Talbot JN, et al. Cancer imaging with fluorine-18-labeled choline derivatives. Semin Nucl Med. 2007;37:420–8.CrossRefPubMed Kwee SA, DeGrado TR, Talbot JN, et al. Cancer imaging with fluorine-18-labeled choline derivatives. Semin Nucl Med. 2007;37:420–8.CrossRefPubMed
11.
go back to reference Behesthi M, Haim S, Zakavi R, et al. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. J Nucl Med. 2013;54:833–40.CrossRef Behesthi M, Haim S, Zakavi R, et al. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. J Nucl Med. 2013;54:833–40.CrossRef
12.
go back to reference Marzola MC, Chondrogiannis S, Ferretti A, et al. Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution. Clin Nucl Med. 2013;38:e26–8.CrossRefPubMed Marzola MC, Chondrogiannis S, Ferretti A, et al. Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution. Clin Nucl Med. 2013;38:e26–8.CrossRefPubMed
Metadata
Title
Detection of Synchronous Parathyroid Adenoma and Breast Cancer with 18F-Fluorocholine PET-CT
Authors
Wessel MCM Vorselaars
Wouter P. Kluijfhout
Menno R. Vriens
Carmen C. van der Pol
Inne HM Borel Rinkes
Gerlof D. Valk
Bart de Keizer
Publication date
01-06-2016
Publisher
Springer Berlin Heidelberg
Published in
Nuclear Medicine and Molecular Imaging / Issue 2/2016
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-015-0357-x

Other articles of this Issue 2/2016

Nuclear Medicine and Molecular Imaging 2/2016 Go to the issue